Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Clinical trial NCT03553836 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03553836
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-12
- Primary completion
- 2021-06-21
- Enrollment
- 976
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.